SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Faculty
Kevin Flaherty, MD, MS
Professor in Pulmonary and Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI

Course Director and Moderator
Fernando J. Martinez, MD, MS
Executive Vice Chairman
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York, NY

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Title
: The Evolution of IPF Diagnosis and Management: Incorporating New Data into Practice
Activity/Course #:
: NCME350
Cost:
: Free
Release/Start Date:
: Apr 01 2018
Expiration Date:
: Mar 31 2019
Topics:
: Pulmonology
Target Audience:
: Pulmonologists and Primary Care Providers
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s)
Hardware/Software Requirements:
Program Summary
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal type of idiopathic interstitial pneumonia, and is a devastating disease associated with irreversible destruction of the lung.
 
In the United States, IPF has a prevalence of about 400,000 cases, and its incidence is 10-40/100,000 adults. IPF is associated with increased comorbidity, healthcare resource utilization, and direct medical costs. The disease has a poorer prognosis than other interstitial lung diseases (ILDs), with a median survival of 3 years from diagnosis.
 
The availability of two effective drugs has improved therapeutic opportunities for IPF patients, but challenges clinicians to provide input and support regarding which agent to consider and how to identify response or disease progression. In practice, diagnostic delay and misdiagnosis are still common, and the condition remains undertreated. This educational program will discuss an approach to diagnosis and treatment of patients with exacerbations of IPF.
 
This webcast was recorded live at the Conversations in Pulmonology 2018 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Discuss the diagnostic approach for IPF incorporating current guidelines and evolving modalities.
  2. Discuss emerging data on longer term outcomes for patients treated with nintedanib or pirfenidone.
  3. Discuss the approach to diagnosis and treatment of patients with exacerbations of IPF

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Fernando Martinez, MD, MS serves as Advisory Board/Steering Committee member to Astra Zeneca, Boehringer Ingelheim, Novartis, Peal, DSMB to Genentech, and Advisor to ProTerrix Bio.

Kevin Flaherty, MD, MS serves as a consultant for Boehringer Ingelheim, Roche-Genetech, Veracyte, and Sanofi Genzyme. Dr. Flaherty also serves as part of the research study team for Boehringer Ingelheim.

Gregg Sherman, MD, Activity Planning Committee, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Sheila Lucas, CWEP, Activity Planning Committee has no relationships to disclose.

Sandy Bihlmeyer, MEd, Activity Planning Committee, has no relationship to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.